Search results for "Extractable nuclear antigens"

showing 3 items of 3 documents

Antibodies to cytoskeletal proteins in patients with Crohn's disease

1990

. The immunologic basis of inflammatory bowel disease has been the focus of interest of a series of studies on Crohn's disease and the process of immune sensitization at the gastrointestinal mucosal level is functionally poorly understood. To date only few contradictory reports concerning the incidence of autoantibodies in patients with this disease exist. The aim of this study was to investigate the sera drawn from 60 patients suffering from biopsy-proven Crohn's disease to evaluate the prevalence of autoantibodies against nuclear antigens and cytoskeletal proteins. Using standard methods, no anti-nuclear antibodies or antibodies to extractable nuclear antigens could be detected. All sera …

AdultMalePathologymedicine.medical_specialtyAdolescentAnti-nuclear antibodyExtractable nuclear antigensClinical BiochemistryBiochemistryInflammatory bowel diseaseImmune systemCrohn DiseaseAntigenmedicineHumansChildAgedAutoantibodiesbiologyAutoantibodyGeneral MedicineMiddle Agedmedicine.diseaseAnti-thyroid autoantibodiesImmunoglobulin ACytoskeletal ProteinsImmunoglobulin MAntibodies AntinuclearImmunoglobulin GImmunologybiology.proteinFemaleAntibodyEuropean Journal of Clinical Investigation
researchProduct

Glycosaminoglycan Antibodies in Endocrine Ophthalmopathy

1993

An increased accumulation of glycosaminoglycans (GAG) in the orbita has been reported in endocrine ophthalmopathy (EO). In this study we investigated whether antibodies directed against GAG are present in the sera of 52 EO patients and 47 healthy controls. Three out of 52 patients exhibited low titers of antinuclear antibodies and all patients were negative for antibodies against extractable nuclear antigens. Isotype IgG antibodies were detected by means of an ELISA using hyaluronic acid and dermatan sulfate as antigens. Values were expressed as optical density at 405 nm. In comparison to the control group (0.445, 0.364, 0.588; median, 25th, 75th percentile) significantly (p < 0.001) higher…

AdultMalemedicine.medical_specialtyAdolescentEye DiseasesAnti-nuclear antibodyExtractable nuclear antigensEndocrinology Diabetes and MetabolismClinical BiochemistryDermatan SulfateBiochemistryDermatan sulfatechemistry.chemical_compoundEndocrinologyAntigenInternal medicineHyaluronic acidmedicineHumansHyaluronic AcidAgedAutoantibodiesGlycosaminoglycansAged 80 and overbiologybusiness.industryBiochemistry (medical)ThyroidAutoantibodyGeneral MedicineMiddle AgedThyroid Diseasesmedicine.anatomical_structureEndocrinologychemistryImmunologybiology.proteinFemaleAntibodybusinessHormone and Metabolic Research
researchProduct

Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-smal…

2019

Immune-checkpoint blockade by Nivolumab, a human monoclonal antibody to programmed cell death receptor-1, is an emerging treatment for metastatic non-small cell lung cancer (mNSCLC). In order to prolong patient survival, this treatment requires a continuous cross-priming of tumor derived-antigens to supply fresh tumor-specific immune-effectors; a phenomenon that may also trigger auto-immune-related adverse events (irAEs). The present study therefore investigated the prognostic value of multiple autoimmunity- associated parameters in patients with mNSCLC who were undergoing Nivolumab treatment. This retrospective study included 92 mNSCLC patients who received salvage therapy with Nivolumab (…

OncologyCancer Researchmedicine.medical_specialtyIrAEExtractable nuclear antigensmedicine.medical_treatmentSalvage therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineLung cancerAdverse effectMNSCLCChemotherapyAuto-antibodiePD-1/PDL-1-blockadebusiness.industryHazard ratioCancerArticlesmedicine.diseaseOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyNivolumabbusiness
researchProduct